Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 2
Submit an article Journal homepage
42
Views
9
CrossRef citations to date
0
Altmetric
Miscellaneous

Medical management of primary pulmonary hypertension

Vallerie V McLaughlin Rush-Presbyterian-St. Luke’s Medical Centre, 1725 W Harrison Street, Suite 020, Chicago, IL 60612, USA, Tel.: +1 312 563-2169; Fax: +1 312 563-2487;, E-mail: [email protected]
Pages 159-165 | Published online: 25 Feb 2005

REFERENCES

  • ABENHAIM L, MORIDE Y, BRENOT F etal.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl. J Med. (1996) 335:609–16.
  • RICH S: Primary pulmonary hypertension In: World Symposium - Primary Pulmonary Hypertension. Rich S (Ed.), (1998). •Available from the WHO via the Internet http://www.who.intlned/evd/pph.htmi
  • CHRISTMAN B, MCPHERSON C, NEWMAN J et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl. J Med. (1992) 327:70–5.
  • GIAID A, SALEH D: Reduced expressionof endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl. I Med. (1995) 333:214–21.
  • GIAID A, YANAGISAWA M, LANGLEBEN D: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl. j Med (1993) 328:1732–9.
  • D'ALONZO G, BARST R, AYRES S et al: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. (1991) 115:343.
  • SANDOVAL J, BAUERLE 0, PALOMAR A et al.: Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation (1994) 89:1733.
  • RICH S, SEIDLITZ M, DODIN E etal.: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest (1998) 114:787–792.
  • FUSTER V, STEEL P, EDWARDS W et al.: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation (1984) 70:580.
  • RICH S, KAUFMAN E, LEVY P: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl. I Med. (1992) 327:76.
  • TUDER R, COOL C, GERACI M et al.:Prostacyclin synthase expression is decreased in lungs from patients with severe pulm-onary hypertension. Am. j Respir: Olt. Care Med. (1999) 159:1925–1932.
  • JONES K, HIGENBOTTAM T, WALLWORK J: Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest (1989) 96:784–89.
  • RUBIN L, MENDOZA J, HOOD M: et al.: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann. Intern. Med. (1990) 112:485–491.
  • BARST R, RUBIN L, MCGOON M, CALD WELL E, LONG W, LEVEY P: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. (1994) 121:409–415.
  • BARST R, RUBIN L, LONG W et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl. j Med. (1996) 334:296–301.
  • MCLAUGHLIN V, GENTHNER D, PANELLA M, RICH S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl. Med (1998) 338:273–7.
  • SHAPIRO S, OUDIZ R, CAO T et al: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J. Am. Coll Cordial (1997) 30:343–9.
  • MCLAUGHLIN V, GENTHNER D, PANELLA M etal.: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann. Intern. Med (1999) 130:740–3.
  • ROSENZWEIG E, KERSTEIN D, BARST R: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation (1999) 99:1858–65.
  • RICH S, MCLAUGHLIN V: The effects ofchronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. j Am. Coll Cordial. (1999) 34:1184–7.
  • MCLAUGHLIN V, BARST R, RICH S et al.: Efficacy and safety of UT-15, a prostacyclin analog for primary pulmonary hypertension. Eur. j Cordial (1999) 20:486.
  • BARST RJ, SIMMONEAU G, RICH S et al.: Efficacy and safety of chronic subcutaneous infusion of UT-15 in pulmonary arterial hypertension (PAH). Circulation (2000) 102:11–100.
  • NAGAYA N, UEMATSU M, OKANO Y et al.: Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. I Am. Coll Cordial (1999) 34:1188–92.
  • HOEPER M, SCHWARZE M, EHLERDING S et al.: Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue. N Engl. j Med (2000) 342:1866–70.
  • GALIE N. GRIGIONI E BACCHI-REGGIANI L et al.: Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur. Clin Invest. (1996) 26:273.
  • CHANNICK RN, SIMONNEAU G, SITBON 0 et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2002). In Press.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.